{"name":"Macrocure Ltd.","slug":"macrocure-ltd","ticker":"","exchange":"","domain":"","description":"Macrocure Ltd. is a biotechnology company focused on developing innovative cell therapy products for various medical conditions. The company's lead product, CureXcell, is in Phase 3 clinical trials, while another product, Activated allogeneic white blood cells, is in Phase 2.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CureXcell","genericName":"CureXcell","slug":"curexcell","indication":"Ischemic stroke","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Activated allogeneic white blood cells","genericName":"Activated allogeneic white blood cells","slug":"activated-allogeneic-white-blood-cells","indication":"Treatment of diabetic foot ulcers","status":"phase_2"}]}],"pipeline":[{"name":"CureXcell","genericName":"CureXcell","slug":"curexcell","phase":"phase_3","mechanism":"CureXcell is a recombinant human thrombolytic enzyme.","indications":["Ischemic stroke","Pulmonary embolism"],"catalyst":""},{"name":"Activated allogeneic white blood cells","genericName":"Activated allogeneic white blood cells","slug":"activated-allogeneic-white-blood-cells","phase":"phase_2","mechanism":"Activated allogeneic white blood cells stimulate the immune system to fight infections and diseases.","indications":["Treatment of diabetic foot ulcers"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOczg2dnVkODBtbVBoaDR3VEdGblRoQUhXZlI2QlI2LXF1ejh3SUFPQkNBYUJXQVptV3hQd2hPVmhMZk5IYktlcnhXNjQwY3A5WGVsQm1Zbkw0NG5jeW9yMlhIdUl2ZzF5dVZGMW9uLUYyXzI4ck9IdURiX0pJNkdmT1QxcEpla0Q0ZTZwVmNicVp4Y05KWGY2NjZ5eFNSTFNxNGxDWjdZVDNTV2s3Vy1ZX2tkdU9mdkFUeUdmY29jYjBhUQ?oc=5","date":"2016-08-29","type":"deal","source":"PR Newswire","summary":"Leap Therapeutics and Macrocure Announce Definitive Merger Agreement - PR Newswire","headline":"Leap Therapeutics and Macrocure Announce Definitive Merger Agreement","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}